TETEC AG has a manufacturing license under Section 13 para. 1 of Germany’s Medicines Law (AMG) for the autologous cartilage cell products NOVOCART® 3D, NOVOCART® Inject and NOVOCART® Disc. Cell cultivation requires a precisely defined time for all NOVOCART® products. This offers some key benefits.
Planning certainty
Patients can be surgically treated more quickly. TETEC can agree a set date for retransplantatation from the moment the cartilage is removed.
High product quality
The manufacturing process developed by TETEC allows the cultivation of autologous chondrocytes in a functional state typical to that of a cartilage, with high type II collagen and aggrecan synthesis capability, thus complying fully with the quality requirements of the GBA The procedure induces the synthesis of cartilage-relevant regeneration factors, without the use of xenogeneic serums and without the use of risky genetic methodologies.
Since the beginning of 2005, we have been using an improved method, with which the specific quality of chondrocytes can be further increased. The scientific knowledge underpinning this method, led to our development team being honored with a prestigious scientific award. We include a comprehensive quality certificate/test record with every transplant.
Practical removal instruments
The removal instruments supplied standardize the process of removal, significantly simplifying the operator's task.
Intensive training
As a new user and working together with Aesculap Akademie GmbH, we offer you the opportunity to acquire the required OP techniques in a workshop (in Tuttlingen, or ‘on tour’), and to discuss the indications, advantages, disadvantages and limits of autologous chondrocyte transplantation with experienced operators. Please contact Aesculap Akademie at the following address for information about dates:
Aesculap Akademie GmbH
Am Aesculap-Platz
78532 Tuttlingen
Tel.: +49 (0)7461 95-2186
Fax: +49 (0)7461 95-2050
www.aesculap-akademie.de
